177 related articles for article (PubMed ID: 36473627)
1. PTEN Loss Expands the Histopathologic Diversity and Lineage Plasticity of Lung Cancers Initiated by Rb1/Trp53 Deletion.
Zhang L; Liu C; Zhang B; Zheng J; Singh PK; Bshara W; Wang J; Gomez EC; Zhang X; Wang Y; Zhu X; Goodrich DW
J Thorac Oncol; 2023 Mar; 18(3):324-338. PubMed ID: 36473627
[TBL] [Abstract][Full Text] [Related]
2. Transformation from EGFR/PTEN co-mutated lung adenocarcinoma to small cell carcinoma in lymph node metastasis.
Hayashi T; Takamochi K; Kohsaka S; Kishikawa S; Suehara Y; Takahashi F; Suzuki K; Saito T; Yao T
Pathol Int; 2020 May; 70(5):295-299. PubMed ID: 32162763
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of TRP53, PTEN, RB1, and/or CDH1 in the ovarian surface epithelium induces ovarian cancer transformation and metastasis.
Shi M; Whorton AE; Sekulovski N; Paquet M; MacLean JA; Song Y; Van Dyke T; Hayashi K
Biol Reprod; 2020 Apr; 102(5):1055-1064. PubMed ID: 31930396
[TBL] [Abstract][Full Text] [Related]
4. Differential development of large-cell neuroendocrine or small-cell lung carcinoma upon inactivation of 4 tumor suppressor genes.
Lázaro S; Pérez-Crespo M; Lorz C; Bernardini A; Oteo M; Enguita AB; Romero E; Hernández P; Tomás L; Morcillo MÁ; Paramio JM; Santos M
Proc Natl Acad Sci U S A; 2019 Oct; 116(44):22300-22306. PubMed ID: 31611390
[TBL] [Abstract][Full Text] [Related]
5. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
[TBL] [Abstract][Full Text] [Related]
6. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.
Ku SY; Rosario S; Wang Y; Mu P; Seshadri M; Goodrich ZW; Goodrich MM; Labbé DP; Gomez EC; Wang J; Long HW; Xu B; Brown M; Loda M; Sawyers CL; Ellis L; Goodrich DW
Science; 2017 Jan; 355(6320):78-83. PubMed ID: 28059767
[TBL] [Abstract][Full Text] [Related]
7. Transformation or tumor heterogeneity: Mutations in EGFR, SOX2, TP53, and RB1 persist in the histological rapid conversion from lung adenocarcinoma to small-cell lung cancer.
Hao L; Chen H; Wang L; Zhou H; Zhang Z; Han J; Hou J; Zhu Y; Zhang H; Wang Q
Thorac Cancer; 2023 Apr; 14(11):1036-1041. PubMed ID: 36810856
[TBL] [Abstract][Full Text] [Related]
8. Two's Company, Three's a Crowd: Rb1/Trp53/Pten Trifecta and Lung Cancer Molecular and Histopathologic Heterogeneity.
Yehia L; Centomo ML; Pandolfi PP; Eng C
J Thorac Oncol; 2023 Mar; 18(3):260-261. PubMed ID: 36842808
[No Abstract] [Full Text] [Related]
9. Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing.
McFadden DG; Papagiannakopoulos T; Taylor-Weiner A; Stewart C; Carter SL; Cibulskis K; Bhutkar A; McKenna A; Dooley A; Vernon A; Sougnez C; Malstrom S; Heimann M; Park J; Chen F; Farago AF; Dayton T; Shefler E; Gabriel S; Getz G; Jacks T
Cell; 2014 Mar; 156(6):1298-1311. PubMed ID: 24630729
[TBL] [Abstract][Full Text] [Related]
10. Targeted Inhibition of the E3 Ligase SCF
Zhao H; Iqbal NJ; Sukrithan V; Nicholas C; Xue Y; Yu C; Locker J; Zou J; Schwartz EL; Zhu L
Cancer Res; 2020 Jun; 80(11):2355-2367. PubMed ID: 32265224
[TBL] [Abstract][Full Text] [Related]
11. Case report: TP53 and RB1 loss may facilitate the transformation from lung adenocarcinoma to small cell lung cancer by expressing neuroendocrine markers.
Li J; Wei B; Feng J; Wu X; Chang Y; Wang Y; Yang X; Zhang H; Han S; Zhang C; Zheng J; Groen HJM; van den Berg A; Ma J; Li H; Guo Y
Front Endocrinol (Lausanne); 2022; 13():1006480. PubMed ID: 36583000
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
[TBL] [Abstract][Full Text] [Related]
13. Trp53 and Rb1 regulate autophagy and ligand-dependent Hedgehog signaling.
Cochrane CR; Vaghjiani V; Szczepny A; Jayasekara WSN; Gonzalez-Rajal A; Kikuchi K; McCaughan GW; Burgess A; Gough DJ; Watkins DN; Cain JE
J Clin Invest; 2020 Aug; 130(8):4006-4018. PubMed ID: 32568216
[TBL] [Abstract][Full Text] [Related]
14. Lineage-restricted neoplasia driven by Myc defaults to small cell lung cancer when combined with loss of p53 and Rb in the airway epithelium.
Chen J; Guanizo A; Luong Q; Jayasekara WSN; Jayasinghe D; Inampudi C; Szczepny A; Garama DJ; Russell PA; Ganju V; Cain JE; Watkins DN; Gough DJ
Oncogene; 2022 Jan; 41(1):138-145. PubMed ID: 34675406
[TBL] [Abstract][Full Text] [Related]
15. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
[TBL] [Abstract][Full Text] [Related]
16. Cells Lacking the
Oser MG; Fonseca R; Chakraborty AA; Brough R; Spektor A; Jennings RB; Flaifel A; Novak JS; Gulati A; Buss E; Younger ST; McBrayer SK; Cowley GS; Bonal DM; Nguyen QD; Brulle-Soumare L; Taylor P; Cairo S; Ryan CJ; Pease EJ; Maratea K; Travers J; Root DE; Signoretti S; Pellman D; Ashton S; Lord CJ; Barry ST; Kaelin WG
Cancer Discov; 2019 Feb; 9(2):230-247. PubMed ID: 30373918
[TBL] [Abstract][Full Text] [Related]
17. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
Marcoux N; Gettinger SN; O'Kane G; Arbour KC; Neal JW; Husain H; Evans TL; Brahmer JR; Muzikansky A; Bonomi PD; Del Prete S; Wurtz A; Farago AF; Dias-Santagata D; Mino-Kenudson M; Reckamp KL; Yu HA; Wakelee HA; Shepherd FA; Piotrowska Z; Sequist LV
J Clin Oncol; 2019 Feb; 37(4):278-285. PubMed ID: 30550363
[TBL] [Abstract][Full Text] [Related]
18. Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures.
Brcic L; Kuchler C; Eidenhammer S; Pabst D; Quehenberger F; Gazdar AF; Popper H
Diagn Pathol; 2019 May; 14(1):47. PubMed ID: 31109352
[TBL] [Abstract][Full Text] [Related]
19. Lineage plasticity in cancer: a shared pathway of therapeutic resistance.
Quintanal-Villalonga Á; Chan JM; Yu HA; Pe'er D; Sawyers CL; Sen T; Rudin CM
Nat Rev Clin Oncol; 2020 Jun; 17(6):360-371. PubMed ID: 32152485
[TBL] [Abstract][Full Text] [Related]
20. A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations.
Kobayashi H; Kosaka T; Nakamura K; Shojo K; Hongo H; Mikami S; Nishihara H; Oya M
BMC Med Genomics; 2021 Oct; 14(1):245. PubMed ID: 34627261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
